• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症鲁棒性和可进化性的起源。

The origins of cancer robustness and evolvability.

机构信息

University of Glasgow, UK.

出版信息

Integr Biol (Camb). 2011 Jan;3(1):17-30. doi: 10.1039/c0ib00046a. Epub 2010 Oct 14.

DOI:10.1039/c0ib00046a
PMID:20944865
Abstract

Unless diagnosed early, many adult cancers remain incurable diseases. This is despite an intense global research effort to develop effective anticancer therapies, calling into question the use of rational drug design strategies in targeting complex disease states such as cancer. A fundamental challenge facing researchers and clinicians is that cancers are inherently robust biological systems, able to survive, adapt and proliferate despite the perturbations resulting from anticancer drugs. It is essential that the mechanisms underlying tumor robustness be formally studied and characterized, as without a thorough understanding of the principles of tumor robustness, strategies to overcome therapy resistance are unlikely to be found. Degeneracy describes the ability of structurally distinct system components (e.g. proteins, pathways, cells, organisms) to be conditionally interchangeable in their contribution to system traits and it has been broadly implicated in the robustness and evolvability of complex biological systems. Here we focus on one of the most important mechanisms underpinning tumor robustness and degeneracy, the cellular heterogeneity that is the hallmark of most solid tumors. Based on a combination of computational, experimental and clinical studies we argue that stochastic noise is an underlying cause of tumor heterogeneity and particularly degeneracy. Drawing from a number of recent data sets, we propose an integrative model for the evolution of therapy resistance, and discuss recent computational studies that propose new therapeutic strategies aimed at defeating the adaptable cancer phenotype.

摘要

除非早期诊断,否则许多成人癌症仍然是不治之症。尽管全球在研发有效抗癌疗法方面投入了大量精力,但这一事实仍令人质疑在针对癌症等复杂疾病状态时使用合理药物设计策略的合理性。研究人员和临床医生面临的一个基本挑战是,癌症是固有的健壮生物系统,即使受到抗癌药物的干扰,它们也能够生存、适应和增殖。从肿瘤健壮性的原则出发,正式研究和描述其潜在机制是至关重要的,如果没有对肿瘤健壮性原则的透彻理解,就不可能找到克服治疗耐药性的策略。简并性描述了结构不同的系统成分(例如蛋白质、途径、细胞、生物体)在对系统特性的贡献上具有条件可互换性,它广泛涉及复杂生物系统的健壮性和可进化性。在这里,我们关注的是支撑肿瘤健壮性和简并性的最重要机制之一,即大多数实体瘤的标志性特征——细胞异质性。基于计算、实验和临床研究的综合分析,我们认为随机噪声是肿瘤异质性,尤其是简并性的根本原因。我们从多个最近的数据集出发,提出了一个用于治疗耐药性进化的综合模型,并讨论了最近的计算研究,这些研究提出了旨在击败适应性癌症表型的新治疗策略。

相似文献

1
The origins of cancer robustness and evolvability.癌症鲁棒性和可进化性的起源。
Integr Biol (Camb). 2011 Jan;3(1):17-30. doi: 10.1039/c0ib00046a. Epub 2010 Oct 14.
2
Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies.转移性疾病的发病机制:对当前治疗及新治疗策略开发的启示
Cancer Treat Rep. 1986 Jan;70(1):183-99.
3
Defining the steps that lead to cancer: replicative telomere erosion, aneuploidy and an epigenetic maturation arrest of tissue stem cells.明确导致癌症的步骤:复制性端粒侵蚀、非整倍体以及组织干细胞的表观遗传成熟停滞。
Med Hypotheses. 2008;71(1):126-40. doi: 10.1016/j.mehy.2008.01.010. Epub 2008 Feb 21.
4
Degeneracy: a design principle for achieving robustness and evolvability.退化:实现鲁棒性和可进化性的设计原则。
J Theor Biol. 2010 Mar 7;263(1):143-53. doi: 10.1016/j.jtbi.2009.11.008. Epub 2009 Nov 17.
5
Cancer stem cells with genetic instability: the best vehicle with the best engine for cancer.具有基因不稳定性的癌症干细胞:癌症的最佳载体与最佳引擎。
Gene Ther. 2008 Jan;15(2):136-42. doi: 10.1038/sj.gt.3303068. Epub 2007 Nov 8.
6
Characterization of stem cells and cancer cells on the basis of gene expression profile stability, plasticity, and robustness: dynamical systems theory of gene expressions under cell-cell interaction explains mutational robustness of differentiated cells and suggests how cancer cells emerge.基于基因表达谱稳定性、可塑性和鲁棒性对干细胞和癌细胞进行表征:细胞间相互作用下基因表达的动力学系统理论解释了分化细胞的突变鲁棒性,并提出了癌细胞是如何出现的。
Bioessays. 2011 Jun;33(6):403-13. doi: 10.1002/bies.201000153. Epub 2011 May 2.
7
Biological robustness.生物稳健性。
Nat Rev Genet. 2004 Nov;5(11):826-37. doi: 10.1038/nrg1471.
8
Genetic and epigenetic heterogeneity in cancer: a genome-centric perspective.癌症中的遗传和表观遗传异质性:以基因组为中心的视角
J Cell Physiol. 2009 Sep;220(3):538-47. doi: 10.1002/jcp.21799.
9
The Challenge of Developing New Therapies for Childhood Cancers.开发儿童癌症新疗法面临的挑战。
Oncologist. 1997;2(1):I-II.
10
Robustness, evolvability, and neutrality.稳健性、可进化性与中性
FEBS Lett. 2005 Mar 21;579(8):1772-8. doi: 10.1016/j.febslet.2005.01.063.

引用本文的文献

1
The regulatory role and mechanism of energy metabolism and immune response in head and neck cancer.能量代谢与免疫反应在头颈癌中的调控作用及机制
Genes Dis. 2025 Mar 19;12(6):101607. doi: 10.1016/j.gendis.2025.101607. eCollection 2025 Nov.
2
Leveraging mesoporous silica nanomaterial for optimal immunotherapeutics against cancer.利用介孔二氧化硅纳米材料实现针对癌症的最佳免疫疗法。
In Vitro Model. 2023 Nov 13;2(5):153-169. doi: 10.1007/s44164-023-00061-0. eCollection 2023 Nov.
3
Lactate: a rising star in tumors and inflammation.
乳酸:肿瘤与炎症领域的一颗新星。
Front Immunol. 2024 Nov 26;15:1496390. doi: 10.3389/fimmu.2024.1496390. eCollection 2024.
4
Combining energy-based focal ablation and immune checkpoint inhibitors: preclinical research and clinical trials.基于能量的聚焦消融与免疫检查点抑制剂联合应用:临床前研究与临床试验
Front Oncol. 2023 May 1;13:1153066. doi: 10.3389/fonc.2023.1153066. eCollection 2023.
5
Integration of single sample and population analysis for understanding immune evasion mechanisms of lung cancer.单细胞与群体分析整合研究以解析肺癌免疫逃逸机制
NPJ Syst Biol Appl. 2023 Feb 10;9(1):4. doi: 10.1038/s41540-023-00267-8.
6
Information geometry for multiparameter models: new perspectives on the origin of simplicity.多参数模型的信息几何:对简单性起源的新视角。
Rep Prog Phys. 2022 Dec 28;86(3). doi: 10.1088/1361-6633/aca6f8.
7
A Pan-Cancer Analysis of the Role of PBRM1 in Human Tumors.PBRM1在人类肿瘤中作用的泛癌分析
Stem Cells Int. 2022 Oct 12;2022:7676541. doi: 10.1155/2022/7676541. eCollection 2022.
8
Multi-Omics Analysis of GNL3L Expression, Prognosis, and Immune Value in Pan-Cancer.泛癌中GNL3L表达、预后及免疫价值的多组学分析
Cancers (Basel). 2022 Sep 22;14(19):4595. doi: 10.3390/cancers14194595.
9
Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition.通过联合免疫检查点抑制和酪氨酸激酶抑制增强抗肿瘤治疗反应。
Mol Cancer. 2022 Sep 29;21(1):189. doi: 10.1186/s12943-022-01656-z.
10
The new progress in cancer immunotherapy.癌症免疫疗法的新进展。
Clin Exp Med. 2023 Jul;23(3):553-567. doi: 10.1007/s10238-022-00887-0. Epub 2022 Sep 15.